What is Vetoquinol?
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region.
0O1O · Verdict
Moderate reward · moderate risk
0O1O stands out on balance sheet and cash flow, but watch the growth signal.
Based on 88% data coverage
0O1O · Verdict
Interest covered 58.4×
11% free-cash-flow margin
Above average
Rev -0.9% CAGR · earnings +6.1%
11% net margin · 10% ROE
Model-based scoring. For information only — not financial advice.
Vetoquinol SA, a veterinary pharmaceutical company, engages in designing, developing, and selling of veterinary drugs and non-medicinal products for cattle, pigs, dogs, and cats in Europe, the Americas, and the Asia Pacific region. It offers products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; antibiotics; reproduction; behavior management; internal medicine; and cardio-nephrology. The company is listed on the LSE in UK, with a market capitalisation of 947.47M, and a P/E ratio of 0.1x.
The scoring profile indicates limited reward potential at this time, with valuation and momentum offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.